BioInvent International AB - Company Profile
Powered by 
All the sales intelligence you need on BioInvent International AB in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BioInvent International AB fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BioInvent International AB.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioInvent International AB (BioInvent) is a biotechnology company. It discovers and develops antibody-based therapies for cancer treatment using its proprietary F.I.R.S.T technology platform to identify therapeutic targets and corresponding antibodies. The company's lead candidate, BI-1808, targets solid tumors and is in a Phase 1/2a trial, as a standalone therapy and with pembrolizumab. BI-1206 aims to enhance the efficacy of treatments for non-Hodgkin lymphoma by blocking the FcγRIIB receptor and is supported by a clinical agreement with AstraZeneca. BI-1607, engineered for reduced Fc binding, is set for a Phase 2 study in metastatic melanoma. It is also collaborating with Transgene on BT-001, an oncolytic virus in a Phase 1/2a study. BioInvent is headquartered in Lund, Sweden.
Headquarters
Sweden
Address
The Gamma Building, Ideongatan 1, Lund, 22370
Website
www.bioinvent.com
Telephone
46 46 2868550
No of Employees
112
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BINV (STO)
Revenue (2024)
$23.1M
406.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
22.5%
(2024 vs 2023)
Market Cap*
$153.1M
Net Profit Margin (2024)
XYZ
84.7%
(2024 vs 2023)
* As of and is in US$
BioInvent International AB premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| BI-1808: Non-Small Cell Lung Cancer and Ovarian Cancer |
| BI-1910: Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Asset Disposal | In May, the company sold its future mezagitamab (TAK-079) royalty and milestone interests to XOMA Royalty Corp for US$20 million. |
| 2025 | Regulatory Approval | In March, the company was granted Orphan Drug Designation by the US FDA for BI-1808 for the treatment of T-cell lymphoma. |
| 2024 | Contracts/Agreements | In July, the company entered into a new clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co Inc to evaluate BI-1607 in combination with keytruda (pembrolizumab) and ipilimumab. |
Competitor Comparison
| Key Parameters | BioInvent International AB | Merck & Co Inc | Pfizer Inc | Bristol-Myers Squibb Co | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | Sweden | United States of America | United States of America | United States of America | United States of America |
| City | Lund | Rahway | New York City | Princeton | Thousand Oaks |
| State/Province | - | New Jersey | New York | New Jersey | California |
| No. of Employees | 112 | 75,000 | 75,000 | 32,500 | 31,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Leonard Kruimer | Chairman | Executive Board | 2018 | 68 |
| Martin Welschof | Chief Executive Officer | Senior Management | 2018 | 65 |
| Stefan Ericsson | Chief Financial Officer | Senior Management | 2016 | 63 |
| Andres McAllister, Ph.D. | Chief Medical Officer | Senior Management | 2017 | 70 |
| Bjorn Frendeus | Chief Scientific Officer | Senior Management | - | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer